[-] Show simple item record

dc.contributor.authorBaskin, Serenaeng
dc.contributor.authorNeher, Jon O.eng
dc.contributor.authorDodson, Sherryeng
dc.date.issued2005eng
dc.description.abstractPatients with diabetes who take thiazolidinediones (TZDs) have a higher incidence of congestive heart failure (CHF) than those who do not; the incidence of CHF is similar with the use of pioglitazone (Actos), troglitazone (Rezulin), or rosiglitazone (Avandia) (strength of recommendation [SOR]: B, based on a large retrospective cohort study). However, patients on regimens that include pioglitazone but not insulin have lower rates of CHF than those taking insulin but not pioglitazone (SOR: B, based on a retrospective cohort study). Still, patients starting any TZD should be warned of the possibility of CHF and should be monitored for its development. TZDs are contraindicated for patients with class III and IV CHF (SOR: C, based on expert opinion).eng
dc.identifier.urihttp://hdl.handle.net/10355/3288eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionClinical Inquiries, 2005 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri--Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesJournal of family practice, 54, no. 08 (August 2005)eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjectglycemic controleng
dc.subjectorgan damageeng
dc.subjectcongestive heart failureeng
dc.subject.lcshGlycemic indexeng
dc.subject.lcshCongestive heart failureeng
dc.subject.lcshDiabeteseng
dc.subject.meshThiazolidinedioneseng
dc.titleDo TZDs increase the risk of heart failure for patients with diabetes?eng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record